Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster
View: Text | PDF
Research Article AIDS/HIV Immunology

Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa

  • Text
  • PDF
Abstract

HIV vaginal transmission accounts for the majority of newly acquired heterosexual infections. However, the mechanism by which HIV spreads from the initial site of viral entry at the mucosal surface of the female genital tract to establish a systemic infection of lymphoid and peripheral tissues is not known. Once the virus exits the mucosa it rapidly spreads to all tissues, leading to CD4+ T cell depletion and the establishment of a viral reservoir that cannot be eliminated with current treatments. Understanding the molecular and cellular requirements for viral dissemination from the genital tract is therefore of great importance, as it could reveal new strategies to lengthen the window of opportunity to target the virus at its entry site in the mucosa where it is the most vulnerable and thus prevent systemic infection. Using HIV vaginal infection of humanized mice as a model of heterosexual transmission, we demonstrate that blocking the ability of leukocytes to respond to chemoattractants prevented HIV from leaving the female genital tract. Furthermore, blocking lymphocyte egress from lymph nodes prevented viremia and infection of the gut. Leukocyte trafficking therefore plays a major role in viral dissemination, and targeting the chemoattractant molecules involved can prevent the establishment of a systemic infection.

Authors

Maud Deruaz, Thomas T. Murooka, Sophina Ji, Marc A. Gavin, Vladimir D. Vrbanac, Judy Lieberman, Andrew M. Tager, Thorsten R. Mempel, Andrew D. Luster

×

Figure 2

CCR7 inhibition did not block HIV dissemination from CVT.

Options: View larger image (or click on image) Download as PowerPoint
CCR7 inhibition did not block HIV dissemination from CVT.
(A) Representa...
(A) Representative flow cytometry plots of 2 experiments showing the percentage of CD4+ T cells expressing CD45RA and CCR7 (top panels) and CCR5 and CCR7 (bottom panels) isolated from the CVT of BLT-NSG (left panels) and from human cervical tissue (right panels). (B) Human and murine CCL19 and CCL21 expression in CVT and iLNs in uninfected (open bars, n = 3) and infected (gray bars, n = 3) BLT-NS mice 2 days postinfection (dpi) as measured by qPCR on tissue cDNA. (C) In vitro chemotaxis assay of human peripheral blood T cells in response to human or murine CCL19 and CCL21 in the presence of CCR7 mAb (αCCR7, gray bars, n = 3) or isotype control (open bars, n = 3). In B and C each dot represents 1 mouse and bars represent mean ± SD. #P < 0.05, ##P < 0.01, ###P < 0.001 by Student’s t test. (D) Scheme of in vivo experimental treatment. BLT-NSG mice received human γ-globulins (hIgG) and murine Fc receptor–blocking mAb (2.4G2) with PBS (control, n = 7) or CCR7 mAb (αCCR7, n = 8) i.p. every third day starting 1 day prior to intravaginal (IVAG) HIV. CCR7 mAb–treated mice received CCR7 mAb IVAG starting 3 hours postinfection (hpi) and control mice received PBS. (E) Numbers of human CD3+ T cells in peripheral blood, LNs, and spleen. (F) Percentage of naive (TN: CD45RA+CD62L+), central memory (TCM: CD45RA–CD62L+), effector memory (TEM: CD45RA–CD62L–) and effector memory reexpressing CD45RA (TEMRA: CD45RA+CD62L–) T cells in LNs and spleen of control-treated (open circles) or CCR7 mAb–treated (closed circles) mice. Each circle in E and F represents 1 mouse and bars represent mean + SD. *P < 0.05, **P < 0.01 by Kruskal-Wallis test and Fisher exact test. Presence of HIV RNA in plasma (G) and tissues (H) at 14 dpi of control or CCR7 mAb–treated mice. Results corresponding to CCR7 mAb–treated mice with positive viremia are shown with different colors. Dotted line: limit of sensitivity of the assay; gray box: ± 2 SD of mean value of 3 to 5 uninfected animals. CVT, cervico-vaginal tissue; LNs, lymph nodes; cLNs, cervical; aLNs, axillary LNs; mLNs, mesenteric LNs.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts